日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

Acalabrutinib 联合 venetoclax 和 rituximab 治疗初治套细胞淋巴瘤:2 年安全性和有效性分析

Michael Wang, Tadeusz Robak, Kami J Maddocks, Tycel Phillips, Stephen D Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity

CCR1 阻断会诱导巨噬细胞表型转变并引发有利的抗淋巴瘤活性

Kang Le, Jing Sun, Javid Ghaemmaghami, Mitchell R Smith, W K Eddie Ip, Tycel Phillips, Mamta Gupta

T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia

TAK-981(Subasumstat)是一种 SUMO 活化酶抑制剂,对慢性淋巴细胞白血病的 T 细胞内在免疫调节作用

Vi Lam, Carly Roleder, Tingting Liu, Nur Bruss, Scott Best, Xiaoguang Wang, Tycel Phillips, Geoffrey Shouse, Allison J Berger, Lapo Alinari, Lili Wang, Tanya Siddiqi, Nathan D Pennock, Alexey V Danilov

Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation

滤泡性淋巴瘤相关 BTK 突变失活,导致 AKT 激活增强

Nan Hu, Fangyang Wang, Tianyu Sun, Zhengfan Xu, Jing Zhang, Denzil Bernard, Shilin Xu, Shaomeng Wang, Mark Kaminski, Suma Devata, Tycel Phillips, Sami N Malek

Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR

滤泡性淋巴瘤相关液泡 ATPase ATP6V1B2 突变激活自噬通量和 mTOR

Fangyang Wang, Damián Gatica, Zhang Xiao Ying, Luke F Peterson, Peter Kim, Denzil Bernard, Kamlai Saiya-Cork, Shaomeng Wang, Mark S Kaminski, Alfred E Chang, Tycel Phillips, Daniel J Klionsky, Sami N Malek

A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas

一项针对复发或难治性皮肤或外周 T 细胞淋巴瘤患者的单中心 II 期研究

Philip S Boonstra, Avery Polk, Noah Brown, Alexandra C Hristov, Nathanael G Bailey, Mark S Kaminski, Tycel Phillips, Sumana Devata, Tera Mayer, Ryan A Wilcox

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas

使用双激酶溴结构域抑制剂 volasertib 抑制 Polo 样激酶 1 (PLK-1) 和 c-myc 治疗侵袭性淋巴瘤

Carlos Murga-Zamalloa, Avery Polk, Walter Hanel, Pinki Chowdhury, Noah Brown, Alexandra C Hristov, Nathanael G Bailey, Tianjiao Wang, Tycel Phillips, Sumana Devata, Pradeep Poonnen, Juan Gomez-Gelvez, Kedar V Inamdar, Ryan A Wilcox